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ABSTRACT 
The nucleotide precursor pool is readily susceptible to numerous sources of modification and 
damage, including alkylation, deamination and oxidation/nitrosylation, among others; most of 
which have deleterious effects on nucleic acid integrity and cellular fitness. In addition to DNA 
repair mechanisms, these metabolic byproducts are kept in check by so-called sanitation or 
“housekeeping” enzymes, chief among them the NUDIX hydrolase superfamily. Increased 
metabolic demand and strain in certain contexts, such as cancer, may require a greater reliance 
on these proteins; therefore, they are attractive drug targets. 
The human NUDIX hydrolase, MTH1 (NUDT1), sanitizes the nucleotide pool of 8-oxo-guanine 
triphosphates, considered the most common oxidative lesion, thereby preventing mutagenesis of 
nucleic acids and preserving their integrity. Other NUDIX enzymes, namely NUDT15 (MTH2) 
and NUDT5, are proposed to perform similar functions as MTH1, and, therefore, may serve as 
resistance mechanisms for cells treated with MTH1 inhibitors. However, very little is known 
about their biological functions in human cells. 
The focus of this thesis was to determine the biological roles of NUDT15 and NUDT5 and if 
they are desirable drug targets for treating cancer. Surprisingly, we found that neither of these 
proteins appeared to be important for oxidized nucleotide metabolism, but, rather, they had 
unexpected and diverse functions in nucleotide metabolism with cancer therapeutic implications. 
These findings should encourage further study of the human NUDIX family. 
In Paper I, we compared NUDT15 biochemically, structurally and in a cellular context to 
MTH1. NUDT15 hydrolyzed 8-oxo-dGTP about 230-fold less efficiently than MTH1, and its 
depletion in cancer cells neither affected cell survival nor oxidized nucleotide content of DNA. 
The NUDT15 crystal structure explained this deviation from MTH1 and shows that 8-oxo-dGTP 
is poorly accommodated in the enzyme active site. We also identified 6-thio-(d)GTP, the active 
metabolites of thiopurine chemotherapeutics, as NUDT15 substrates. 
In Paper II, we expounded upon the role of NUDT15 in thiopurine metabolism and why the 
R139C missense mutant causes thiopurine intolerance in patients. NUDT15 efficiently 
hydrolyzes 6-thio-(d)GTP, thus mediating the amount of the active thiopurine metabolites in 
cells. In addition, the R139C mutation does not impact catalytic ability of NUDT15, but rather 
causes destabilization of the protein structure and proteolytic degradation in cells, thus 
explaining why patients with this mutation are sensitive to thiopurine treatments. 
Paper III presents further evidence that NUDT5 may not be an important contributor to 
sanitation of the oxidized nucleotide pool, describes the first small molecule NUDT5 inhibitors 
and confirms the nuclear ATP synthetic role for NUDT5 in breast cancer cells.  Following an 
initial screening campaign and medicinal chemistry efforts, potent, cell-active NUDT5 inhibitors 
were identified using a CETSA-guided screening funnel. Lead compound, TH5427, abrogated 
progestin-dependent gene regulation and proliferation in breast cancer cells, thus, representing a 
bonafide probe to further study NUDT5 biology. 
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